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Introduction: Definitive locoregional therapy including surgery and post-mastectomy radiation therapy (PMRT) has
been offered to select IBC patients with de novo metastatic disease. Herein we examined predictive factors for
progression-free survival after comprehensive PMRT radiation +/- locoregional treatment of metastatic sites.
Methods: Charts of T4d, any N, M1 (de novo) patients who completed PMRT to ≥ 50 Gy from 2006–2011 were
reviewed. Patients who received doses <50Gy to the primary site, received radiation at another facility or were
treated pre-operatively were excluded. The remaining 36 patients formed the study cohort. Progression-free survival
post-PMRT (PFSx) was assessed from the last day of radiation. Median dose to primary fields was 51 Gy. Boost doses
ranged from 6–16 Gy.
Results: Median age at diagnosis was 54 (range 33–70). Median follow up from primary irradiation completion was
31 months. Sixteen patients were Stage IV NED at last follow-up (IR 37–60 mo). Fifteen patients died of disease. Five
patients experienced an in-field recurrence, three of which resulted from local recurrence at the medial edge of the
field. Actuarial 5 year locoregional control (LRC) was 86%. Median PFSx was 20 months. All sites of gross disease
were treated with radiation in 21/36 patients. Location of metastatic disease had no correlation with PFSx. Estrogen
receptor (ER)- patients had shorter 5-yr actuarial PFSx (28% vs. 66%, P = 0.03) and 5 year actuarial OSx (37% vs 71%,
P = 0.02). Nine patients (25%) developed a pathological complete response (pCR) after chemotherapy and with a
median follow-up of 59 months, 7 remained without evidence of disease.
Conclusions: Despite the poor prognosis associated with metastatic IBC, our data suggest that select patients may
be appropriate candidates for locoregional therapy. Patients who achieve a pCR or those with ER + disease have a
favorable PFSx. It remains unclear whether all gross disease needs to be addressed with locoregional therapy to
provide benefit.
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Historically, a diagnosis of inflammatory breast cancer
(IBC) was uniformly fatal with 5 year overall survival (OS)
rates <5% in multiple studies in the 1970s with a median
survival of 1.2 years. (Robbins et al. 1974; Stocks and
Patterson 1976; Zucali et al. 1976) However, the advent of
polychemotherapy and endocrine therapy has led to im-
proved survival as demonstrated in large meta-analyses as
well as in our large (n = 398) single institutional experi-
ence of patients treated for IBC, with 5 year OS reported
to be 46.1% at a median follow up of 5.8 years. (Early
Breast Cancer Trialists’ Collaborative Group 1988, 1998;
Gonzalez-Angulo et al. 2007) These values stand in stark
contrast to the 5 year OS of 79.2% reported for a contem-
porary population of non-metastatic breast cancer patients
treated with multimodality therapy (Greenbaum et al.
2010). Although IBC is still considered to be the most ag-
gressive form of breast cancer, there have clearly been im-
provements in treatment paradigms over the decades
(Anderson et al. 2003). However, given the relative rarity
of IBC (1–3% of breast cancers), there is limited data on
stage IV (de novo) IBC at presentation, and essentially
none on the role of aggressive radiation therapy in this set-
ting (Wingo et al. 2004).
IBC is a clinical diagnosis, encompassing the rapid onset
of diffuse erythema and edema of the breast in the absence
or presence of a discrete mass (AJCC 2010). By definition,
the symptoms must have developed over <6 months and
involve >1/3 of the breast. Additional presenting symptoms
can include pain, tenderness, and ulceration (Jaiyesimi
et al. 1992). Although dermal lymphatic invasion is a char-
acteristic pathologic finding, it is not required for diagnosis
(Dawood et al. 2011).
Patients with non-metastatic IBC face the prospect of
a lengthy definitive treatment course, consisting of neo-
adjuvant chemotherapy, modified radical mastectomy,
post-operative radiation therapy, and adjuvant systemic
therapy, if warranted. Neoadjuvant chemotherapy forms
the cornerstone of treatment, demonstrating improved
disease-free and overall survival for IBC patients (Ueno
et al. 1997). Pathologic response in the breast and lymph
nodes is considered to be highly prognostic (Buzdar
et al. 1995; Rouesse et al. 1986; Rouzier et al. 2002). In a
series of 54 patients with IBC, 10 yr OS was 35% in all
patients, however if there was pCR after neoadjuvant
chemotherapy, 50% of patients achieved 10 year DFSx.
Lymph node involvement is also considered to be prog-
nostic(Jaiyesimi et al. 1992; Lerebours et al. 2003) as is
extensive erythema, negative hormone receptor status,
and p53 gene mutation (Chevallier et al. 1987; Riou
et al. 1993). Given that lymph node metastases are
therefore both common and prognostic, the benefit of
neoadjuvant chemotherapy is attributed to the ability to
address subclinical sites of metastatic disease with theunderlying hypothesis that IBC likely represents a sys-
temic process from the start. This logic is further sup-
ported by studies such as that by Tabanne et al. who
note metastases within 2 months of locoregional treat-
ment, despite no evidence of metastatic (M1) disease on
initial staging workup (Tabbane et al. 1977).
Pending a response to neo-adjuvant systemic treatment,
patients are then considered for modified radical mastec-
tomy prior to consolidative radiation therapy, which has a
demonstrated locoregional control (LRC) benefit (Fleming
et al. 1997; Schafer et al. 1987). However, this multimo-
dality treatment paradigm is typically not applied to all
patients with M1 disease that could be feasibly and safely
eradicated by local therapy. Traditionally, M1 disease,
Stage IV, has been treated by systemic therapy alone with
palliative local therapy as indicated. However, in the
setting of effective systemic treatment to address distant
subclinical sites of disease and feasible options for consoli-
dative local therapy (radiation and surgery), the definitive
paradigm has been applied in select cases presenting with
Stage IV IBC. A recent retrospective report by Akay et al.
including 172 cases of metastatic IBC reports increased
overall survival and distant progression-free survival in
those patients who received chemotherapy along with
radiotherapy and surgery in comparison to those that re-
ceived chemotherapy with either surgery or radiotherapy
alone (Akay et al. 2014).
Here, we review in greater detail the subset of these pa-
tients representing a contemporary, single-institutional co-
hort of women treated for Stage IV IBC, in a dedicated
multi-disciplinary IBC clinic, with neoadjuvant chemo-
therapy, followed by definitive locoregional treatment,
comprised of surgery and post-mastectomy radiation ther-
apy to ≥50 Gy. Study objectives included evaluation of
clinical outcomes in this population subset as well as iden-
tification of factors to guide medical decision making in
these challenging clinical scenarios.
Methods
Patients
This study was approved by the Institutional Review Board
at The University of Texas, MD Anderson Cancer Center.
The institution and State of Texas dedicated resources to
an IBC clinic in 2006. We retrospectively reviewed med-
ical records for all patients diagnosed with T4d Nany M1
(de novo) inflammatory breast cancer from 2006–2011.
Only those patients who were found to have metastases
within 3 months of IBC diagnosis were considered. Sixty-
four percent of these patients (n = 117) did not receive
radiation therapy or surgery. Fifty-three patients were
identified who had completed post-mastectomy radiation
therapy (PMRT). Sixteen patients who received palliative
radiotherapy to <50 Gy to the primary site or were treated
pre-operatively were excluded. An additional patient who
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reirradiated at our institution was also excluded. The
remaining 36 patients form the current study population.
Prior to treatment, all patients underwent appropriate
staging workup as well as multidisciplinary consultation
in our Breast Center. Medical photographs were taken
prior to chemotherapy to guide eventual radiation field
design. All patients had pathology confirmed by our in-
house pathologist. Metastatic sites were confirmed by
ultrasound or CT-guided biopsies when appropriate and
feasible. All patients in this series received neoadjuvant
chemotherapy, consisting of weekly Taxol for 12 weeks
followed by either FAC (5-fluorouracil, Adriamycin, and
cyclophosphamide) or FEC (5-fluorouracil, epirubicin,
and cyclophosphamide) every three weeks for four cy-
cles, per institutional practice. All estrogen receptor (ER)
or HER-2/neu positive patients received appropriately
targeted therapies under the supervision of a medical
oncologist.
After modified radical mastectomy, no evidence of dis-
ease by pathology review of the breast and lymph nodes
was considered to be a pathologic complete response
(pCR). Pathologic CR does not imply that a site of meta-
static disease was resected. Review of post-chemotherapy
imaging at the time of consultation for comprehensive
post-mastectomy radiation therapy was considered a
radiographic complete response (rCR).
Pre-chemotherapy cross-sectional imaging was used to
delineate target volumes. A combination of 6 and 18 MV
photons were used to treat the chest wall and axillae as re-
quired to provide sufficient dose to the target volume.
Clinically appropriate electron energies were chosen to
treat the supraclavicular and internal mammary lymph
nodes chains. An appositional photon field with a half-
beam block was used to treat the supraclavicular fossae.
Electron supplements were also used to boost nodal basins
that were involved prior to chemotherapy and not oncolo-
gically dissected, to a definitive dose.
Of the 36 patients, 34 were treated exclusively with a 3D
conformal approach using a combination of photons and
electrons. One patient received radiation therapy to the
supraclavicular fossa with intensity-modulated radiation
therapy (IMRT) to allow for concurrent radiation therapy
to her metastatic disease in the C5 vertebral body. A sec-
ond patient received proton beam radiation therapy to
reach her anterior mediastinal metastasis but minimize
lung dose. All patient histories and treatment plans were
reviewed at the Breast Radiation Oncology Quality Assur-
ance meeting. Tissue equivalent bolus schedules varied
depending on fractionation and dermatitis.
Follow up for each patient consisted of visitation with
the medical oncologist to discuss further systemic treat-
ment options if appropriate, as well as appointments
with the treating radiation oncologist at least once every2–4 months for the first two years after completing treat-
ment, with appropriate imaging, or earlier if there were
concerns about radiation-induced complications or dis-
ease progression. Patients were seen every 4–6 months
thereafter. NED status was based on radiographic reports.
All locoregional recurrences (LRR), in the chest wall or ip-
silateral draining lymphatic nodal basins, as identified by
diagnostic imaging or physical examination were con-
firmed by biopsy.
Data analysis
Progression-free survival was assessed from the last day
of radiation therapy to the primary site. NED status was
based on response to radiation therapy, metastasectomy
or systemic treatment. Patients with no evidence of
local or distant disease, based on clinical and radio-
graphic information, at last follow up, were deemed to
be progression-free, stage IV NED. All actuarial Kaplan-
Meier and log rank statistical analyses were performed
using SPSS Statistics 21.0 (IBM Corporation).
Results
Patient characteristics
All 36 patients had clinical presentations consistent with
T4d, inflammatory breast cancer using the international
consensus definition (AJCC 2010). Detailed patient char-
acteristics are presented in Table 1. Median age at time
of diagnosis was 54 years (range 33–70 years). Twenty-
four patients had M1 disease involving lymph nodes. Of
the 16 patients that were ER+, 15 were prescribed endo-
crine therapy. Of the 36 patients, 19 (53%) underwent
biopsy of the metastatic site. Two of these patients (with
M1 disease in the contralateral supraclavicular area and
retroperitoneal area) were found to have negative biop-
sies which were considered to be falsely negative in the
setting of substantial radiologic evidence of disease. Of
the patients that did not undergo biopsy to their site of
M1 disease, the largest fraction (8 patients) had bone
involvement.
Treatment properties
Neoadjuvant chemotherapy was followed by modified rad-
ical mastectomy and radiation therapy to the chest wall
and ipsilateral regional lymph node basins and M1 sites
when feasible and safe. Patients generally received treat-
ment to 50–54 Gy in 2 Gy per fraction (22 patients) or
51 Gy in 1.5 Gy fractions twice daily (14 patients). The pa-
tients treated twice daily met at least one high risk criteria
including poor response to neoadjuvant systemic treat-
ment, positive margins after surgery, or age <45 years
(Bristol et al. 2008). The mastectomy scar and chest wall
were then boosted with appropriate electron energy an
additional 10 Gy to 15 Gy dependent on fractionation.
Fifteen patients received a boost to the infraclavicular
Table 1 Patient Characteristics













ER+, H2N- 12 (33)
ER-, H2N- 10 (28)
ER-, H2N+ 8 (22)
ER+, H2N+ 6 (17)




Contralateral axillary LN 11
Mediastinal LN 8
Contralateral SCV LN 3





PMRT +/- select M1 13(36)
PMRT + All M1 23(64)
Regional LN involved
Internal mammary LN 6
Infraclavicular LN 17
Supraclavicular LN 13
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underwent a boost to the supraclavicular lymph nodes with
doses ranging from 6 to 16 Gy as deemed clinically appro-
priate by the treating physician. Two patients received con-
current chemotherapy with capecitabine (825 mg/m2 twice
daily).
Of the 36 patients, 18 had a radiographic complete re-
sponse (rCR) to neoadjuvant systemic treatment. Of these
patients, nine patients (50%) had a pathologic complete re-
sponse on evaluation of the breast and lymph node tissue.
For 23 of the 36 patients, all sites of metastatic diseasewere addressed by local therapy (surgery and/or radiation
therapy), with 21 of these patients receiving radiation to
all sites of metastatic disease. Two patients, with ovarian
metastatic disease and liver metastasis underwent surgery
to address their sites of M1 disease.
Disease control
Median follow up from primary radiation therapy com-
pletion was 31 months (interquartile range [IR] 18–
55 months). At 2 years follow up, actuarial OSx was 71%,
PFSx after PMRT was 50%, and LRC was 86% (Figure 1).
At 5 years, these values were 54%, 47%, and 86% respect-
ively. In total, 20 patients experienced disease progression,
with 15 patients dying of their disease. There were 5 local
recurrences. Three of these patients failed at the medial
border of the treatment field, with one of these patients
recurring broadly, and a second patient also presenting
with disease recurrence inferior to the field. Among the
final two patients who experienced a local chest wall re-
currence, one was centered within the field and one oc-
curred prior to radiation therapy commencement. Of all
patients, sixteen (44%) were Stage IV with no evidence of
disease (NED) as of last follow-up (median follow-up
in this cohort was 51 months with IR 37–60 months).
Characteristics of this subset of patients are presented in
Table 2.
Prognostic factors for durable NED
To evaluate for prognostic factors that may predict for im-
proved outcome, patients were stratified into subgroups
for further analysis. Five-year actuarial OSx and PFSx were
significantly lower among those patients whose disease
was ER negative (OSx: 37 months vs 71 months, p = 0.02;
PFSx: 28 vs 66 months, p = 0.03) (Figure 2). Her-2/neu
positivity did not significantly affect 5 year OSx (p = 0.07)
or PFSx (p = 0.10). In patients who had a pathologic
complete response (pCR) to systemic treatment, 5 year
OSx was significantly improved as shown in Figure 3A
(88% vs 40%; p = 0.02) as was 5 year PFSx as shown in
Figure 3B (78% vs 36%, p = 0.02). Of 9 patients who
achieved pCR, 7 remained without evidence of disease at
last follow up. OSx and PFSx were no longer significantly
different if patients with complete radiographic response
to systemic treatment were included in the good response
cohort (p = 0.08, p = 0.30 respectively). Comparing pa-
tients who could safely and feasibly receive radiation ther-
apy to all sites of metastatic involvement, with those who
did not receive radiation to all sites, there was no differ-
ence in OSx or PFSx (p = 0.64, p = 0.87 respectively) as
demonstrated in Figure 4. Location of metastatic disease
had no effect on OSx (p = 0.67) or PFSx (p = 0.49) by log-
rank analysis.
For hypothesis generation, we further examined the
outcome by response among PMRT patients for who all
Figure 1 Actuarial disease outcomes for patients treated with neoadjuvant chemotherapy, modified radical mastectomy, and post-
mastectomy radiation therapy. (A) overall survival rate, (B) progression-free survival after PMRT, and (C) locoregional control rate.
Takiar et al. SpringerPlus 2014, 3:166 Page 5 of 9
http://www.springerplus.com/content/3/1/166metastatic deposits could be safely irradiated versus
those in whom only what could be encompassed feasibly
was irradiated. Although the numbers are small, examin-
ing the nine patients who had a pCR, eighteen who had
either a pCR or rCR to systemic therapy, or the 27 who
did not have a pCR to systemic therapy there is no sig-
nificant difference between those in whom all metastatic
deposits were treated and those who received PMRT
without covering all sites of metastatic disease. Further,
although the actuarial PFSx is higher in patients whoTable 2 Characteristics of sixteen patients currently NED
Characteristic N (% of 16 patients)
Receptor Status
ER+, H2N- 5 (31)
ER-, H2N- 2 (13)
ER-, H2N+ 3 (19)
ER+, H2N+ 6 (38)
Radiation Sites
PMRT +/- select M1 6 (38)
PMRT + All M1 10 (62)
Site of M1 disease
Bone 4 (25)
Lung 2 (13)
Contralateral axillary LN 3 (19)
Mediastinal LN 3 (19)
Contralateral SCV LN 1 (6)





rCR or pCR 9 (56)
no pCR 9 (56)achieve a complete radiographic response where all M1
disease was irradiated (80% vs 46%, P = NS), there are
durable (>2-yr) progression free patients in both subsets
where all sites were treated as well as those where not
all sites were treated.
Discussion
IBC remains an extremely aggressive form of breast can-
cer with a poor prognosis and high rates of distant disease
recurrence. Given this, aggressive locoregional therapy
more typical of definitive treatment is generally considered
futile in metastatic patients. We report for the first time,
durable stage IV NED status in highly selected patients
with metastatic IBC treated with contemporary first-line
chemotherapy regimens and aggressive locoregional ther-
apy. We find that comprehensive treatment including neo-
adjuvant chemotherapy, modified radical mastectomy and
comprehensive PMRT which includes all metastatic foci
when feasible was associated with surprisingly durable
NED status. In addition, pCR in the metastatic IBC setting
is a powerful predictor for outcome. Our data suggest ag-
gressive therapy even in patients with this advanced pres-
entation is warranted in select cases.
The primary objective of our study was to retrospect-
ively review our single-institutional experience in the
treatment of stage IV IBC patients with metastatic dis-
ease that have completed neoadjuvant chemotherapy,
modified radical mastectomy, and post-mastectomy radi-
ation therapy to at least 50 Gy. This cohort included pa-
tients with visceral disease and multiple sites of disease
and thus is not exclusively an oligometastatic cohort.
We report a surprisingly high 5-yr OSx of 54% which is
similar to outcomes reported for stage III IBC patients
who complete similar therapy (Scotti et al. 2013). Sur-
prisingly, sixteen patients remain stage IV NED, 12 with
follow up over three years.
The second objective of our analysis was to identify
prognostic factors to predict which patients may benefit
Figure 2 Estrogen receptor positivity results in improved outcomes in Stage IV IBC patients after PMRT. (A) overall survival
(B) progression-free survival.
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metastatic disease and to provide prognostic information
to patients who have achieved stage IV NED status and
completed multi-modality treatment. In our study, pa-
tients who were hormone receptor positive fared better
in terms of both OS and PFS, which is highly consistent
with previously published data supporting the use of ap-
propriately targeted therapies (Harris et al. 2003; Hurley
et al. 2006; Van Pelt et al. 2003). Patients who experi-
enced a pCR also had more durable PFS after PMRT, re-
gardless of the type of metastatic disease, suggesting thatFigure 3 Pathologic complete response to neoadjuvant chemotherap
PMRT. (A) overall survival (B) progression-free survival.perhaps these patient’s tumors have more “favorable
biology”. Interestingly, however, disease control out-
comes were not different if all sites of distant disease
could not be safely or feasibly irradiated. This conclusion
also held true on subset analysis with patients who had a
pCR only, a pathologic or radiographic CR, or no pCR.
We did have 5 patients diagnosed with a locoregional
recurrence in our study cohort with one patient recur-
ring prior to starting radiation therapy, and four recur-
ring after PMRT for a 5-yr actuarial LRR of 14% at a
median follow-up of 31 months. Nearly all of thesey results in improved outcomes in Stage IV IBC patients after
Figure 4 Treating all sites of metastatic disease with radiation therapy does not result in improved outcomes in Stage IV IBC patients
after PMRT. (A) overall survival and (B) progression-free survival.
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therapy which supports our clinical practice of following
these patients closely immediately after they have fin-
ished treatment. This parallels the range of 8–22% de-
scribed in the literature at 5 years in stage III IBC
patients (Harris et al. 2003; Pisansky et al. 1992). Inter-
estingly, three of the five failures encompassed the skin
just outside of the medial border of the radiation field
(Figure 5). This area is often treated conservatively in
order to minimize radiation therapy to the contralateral
breast; however, our review demonstrates the need for
carefully weighing the radiation treatment margin with
the probability of recurrence in this area as failure adja-
cent to the prior radiation field is significantly more dif-
ficult to treat, with increased morbidity. RadiotherapyFigure 5 Representative patient images. (A) medical photograph of a p
treatment field 6 months after completing neo-adjuvant systemic therapy,
with outlined induration and erythema which were biopsy-proven as recur
plan (after recurrence), with purple colorwash delineating the radiation treahas historically been associated with a reduction in LRR
of 2/3 of the baseline risk although the influence of re-
ceptor type likely influences this (Kyndi et al. 2008).
Even conservatively assuming a 50% reduction, these
LRR rates suggest the baseline risk approaches 30% and
highlights the value in preventing the morbidity of LRR
in stage IV IBC. This is of particular interest in IBC
given the potential for very morbid “en cuirasse”, armor-
like local recurrence encircling the thorax.
As with any retrospective approach, there are limita-
tions to this study. We had no a priori eligibility criteria
for referral for surgery and PMRT. On opening a dedi-
cated IBC clinic, patients were typically seen at presenta-
tion by all disciplines regardless of stage or prior to
completing the staging which likely facilitated referralatient with a local recurrence adjacent to the medial edge of the
modified radical mastectomy, and post-mastectomy radiation therapy
rence. (B) skin rendering of the patient’s second radiation treatment
tment field.
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course indicates a selection bias which cannot be fully
accounted for. Patients who progressed on chemother-
apy or who were not amenable to margin negative mast-
ectomy were excluded from this approach. Our study
cohort is carefully selected to include only those patients
with limited metastatic disease who also had a sufficient
response to chemotherapy to warrant further local ther-
apy. Our results in these stage IV patients corroborate
multiple reports in stage III patients suggesting a pCR is
prognostic and suggest response to chemotherapy may
be as important as stage in this cohort. The role of a
radiographic CR in our study remains unclear, and there
are insufficient numbers to demonstrate value in radiat-
ing all involved sites. Furthermore, our study has a me-
dian follow up of 31 months after radiation therapy
which somewhat limits our ability to compare our re-
sults with those of Stage III IBC patients who often have
longer follow up.
Overall, the results are compelling and suggest that
perhaps Stage IV IBC is only slightly further along the
clinical spectrum than Stage III IBC which may harbor
subclinical sites of disease that shortly thereafter mani-
fest as disease progression (Tabbane et al. 1977). These
results also suggest that T4d staging alone should not
preclude patients with limited foci of metastatic disease
from consideration of locoregional treatment, particu-
larly those patients who have had a radiographic CR
who therefore may be recognized as having a pCR at
surgery, and those who are hormone receptor positive.
Further, local control is a significant issue for this
population. Understanding the limitations of the data,
we recommend treating all distant sites at the time of
PMRT in stage IV IBC only when feasible and reason-
ably low risk and we recognize constraining the medial
border of the chest wall field to midline may be inad-
equate margin on the medial scar in IBC. Further valid-
ation of these studies may suggest that increased
incorporation of aggressive locoregional therapies in spe-
cific subsets of patients with metastatic IBC is war-
ranted. Clearly some of these stage IV IBC patients have
achieved a durable NED status potentially suggesting
that some stage IV disease in IBC may represent ex-
tended regional lymphatic spread which may be poten-
tially curable in the setting of effective chemotherapy.
With further study this could also lead to the consider-
ation of patients with focal metastatic disease or extended
regional disease as a distinct staging category.
Conclusions
The degree to which all gross disease needs to be ad-
dressed with locoregional therapy remains unclear. How-
ever, in the absence of randomized trials, these data
suggest that aggressive, local therapy should be consideredin select cases where the potential for locoregional control
outweighs the risks of treatment. In addition, medial
PMRT margins need to be generous, and targeting M1
disease should balance the potential for sterilization of all
disease with toxicity and feasibility in all patients. We cur-
rently reserve this approach for patients who have no
gross radiographic disease at the time of PMRT, or those
in whom gross disease is easily and safely encompassed in
limited fields to high or definitive dose.
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